According to Zacks, “SomaLogic Inc. provides AI-data driven proteomics technology. SomaLogic Inc., formerly known as CM Life Sciences II Inc., is based in NEW YORK. “
Separately, Stifel Nicolaus initiated coverage on SomaLogic in a research report on Tuesday, February 1st. They issued a buy rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Buy and a consensus target price of $16.00.
SomaLogic (NASDAQ:SLGC – Get Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Research analysts expect that SomaLogic will post -0.69 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of SLGC. Sargent Bickham Lagudis LLC purchased a new position in SomaLogic in the first quarter worth approximately $34,000. Wolverine Asset Management LLC purchased a new position in shares of SomaLogic during the fourth quarter worth $36,000. PNC Financial Services Group Inc. purchased a new position in shares of SomaLogic during the third quarter worth $37,000. UBS Group AG purchased a new position in shares of SomaLogic during the third quarter worth $58,000. Finally, Penserra Capital Management LLC purchased a new position in shares of SomaLogic during the fourth quarter worth $98,000. Institutional investors own 58.65% of the company’s stock.
SomaLogic Company Profile (Get Rating)
SomaLogic, Inc operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.
- Get a free copy of the StockNews.com research report on SomaLogic (SLGC)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SomaLogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SomaLogic and related companies with MarketBeat.com's FREE daily email newsletter.